Therapy
Research And Development
Health
Sangamo Therapeutics
$9.209876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$9.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.31 (3.49%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SGMO and other stocks, options, ETFs, and crypto commission-free!
About
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. Read More The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Employees
302
Headquarters
Richmond, California
Founded
1995
Market Cap
908.45M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.21M
High Today
$9.27
Low Today
$8.76
Open Price
$8.99
Volume
557.44K
52 Week High
$22.90
52 Week Low
$6.26
Collections
Therapy
Research And Development
Health
Biotechnology
Engineering
Technology
News
Yahoo FinanceMar 19
Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Sangamo Therapeutics Inc Earnings Call RICHMOND Mar 19, 2019 (Thomson StreetEvents) -- Edited Transcript of Sangamo Therapeutics Inc earnings conference call or presentation Thursday, February 28, 2019 at 10:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Adrian Woolfson Sangamo Therapeutics, Inc. - EVP of Research an...
Seeking AlphaMar 13
March Outlook For Sangamo Therapeutics
Sangamo Therapeutics (SGMO) price action continues to trade within the downward channel that has been in play since September 2018. SGMO has continued to feel the effects of the poor performance in the MPS clinical trials of its proposed medication for the treatment of Hunter's syndrome.
Yahoo FinanceMar 12
What Type Of Shareholder Owns Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO)?
The big shareholder groups in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that have been privatized tend to have low insider ownership. Sangamo Therapeutics isn’t enormous, but it’s not particularly small either. It has a market capitalization of US$1.0b, which means it would generally expect to see some institutions on the share registry. In th...
Price Paid on Robinhood
31% Lower
Right Now
52 Week Low
$6.26
Average Price Paid
$13.35
52 Week High
$22.90
Earnings
-$0.23
$0.01
$0.24
$0.48
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 8, After Hours